Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Methotrexate May Cure up to 20% of Patients With Rare Brain Tumor
Link ID 2754
Title Methotrexate May Cure up to 20% of Patients With Rare Brain Tumor
Url http://www.medscape.com/viewarticle/569341?src=rss
Description New research shows that high-dose methotrexate is the most effective drug for primary central nervous system lymphoma, with up to 20% of patients achieving a long-term remission with methotrexate alone. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Jan 29, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Treatment With VEGF Inhibitors May Cause Renal Thrombotic Microangiopathy
  VEGF inhibitors, such as bevacizumab, may cause glomerular disease that is characteristic of thrombotic microangiopathy. Medscape Medical News
Category:   Articles > Hematology-Oncology


2. ASH 2007: Other Hematologic Malignancies - Multiple Myeloma and Myelodysplastic Syndromes
  Read highlights of the latest findings on the treatment of multiple myeloma and myelodysplastic syndromes. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


3. International Approvals: Torisel, Rocephin, Sigmart
  Europe has approved temsirolimus injection (Torisel); Japan has approved a new dosing regimen for ceftriaxone injection (Rocephin) and an expanded indication for nicorandil injection (Sigmart). Medscape Medical News
Category:   Articles > Hematology-Oncology


4. NCCN 2nd Annual Congress: Hematologic Malignancies - Blood Products and Growth Factors in the Treatm
  Review some of the most current NCCN guidelines on blood products and growth factors for use in thrombocytopenia.
Category:   Articles > Hematology-Oncology


5. Therapy Insight: Anthracyclines and Trastuzumab - The Optimal Management of Cardiotoxic Side Effects
  Trastuzumab may significantly improve survival among women with advanced breast cancer, but there are concerns about cardiotoxicity associated with this targeted therapy. The current analysis examines this issue and means to prevent cardiac events among women receiving trastuzumab. Nature Clinical Practice Oncology
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS